Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,375 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200.
Harada K, Doki N, Miyazaki Y, Wakita A, Ohtake S, Takada S, Komatsu H, Kubo K, Takeshita A, Adachi Y, Kiyoi H, Yamaguchi T, Yoshida M, Naoe T, Ohashi K. Harada K, et al. Among authors: yamaguchi t. Ann Hematol. 2018 Aug;97(8):1481-1483. doi: 10.1007/s00277-018-3281-1. Epub 2018 Mar 1. Ann Hematol. 2018. PMID: 29497807 Clinical Trial. No abstract available.
Myeloablative unrelated cord blood transplantation for acute leukemia patients between 50 and 55 years of age: single institutional retrospective comparison with patients younger than 50 years of age.
Konuma T, Takahashi S, Ooi J, Tomonari A, Tsukada N, Kato S, Sato A, Monma F, Kasahara S, Nagamura-Inoue T, Uchimaru K, Iseki T, Tojo A, Yamaguchi T, Asano S. Konuma T, et al. Among authors: yamaguchi t. Ann Hematol. 2009 Jun;88(6):581-8. doi: 10.1007/s00277-008-0641-2. Epub 2008 Nov 22. Ann Hematol. 2009. PMID: 19030858
Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study.
Wakita A, Ohtake S, Takada S, Yagasaki F, Komatsu H, Miyazaki Y, Kubo K, Kimura Y, Takeshita A, Adachi Y, Kiyoi H, Yamaguchi T, Yoshida M, Ohnishi K, Miyawaki S, Naoe T, Ueda R, Ohno R. Wakita A, et al. Among authors: yamaguchi t. Int J Hematol. 2012 Jul;96(1):84-93. doi: 10.1007/s12185-012-1105-y. Epub 2012 May 26. Int J Hematol. 2012. PMID: 22639053 Clinical Trial.
Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Takami A, Yano S, Yokoyama H, Kuwatsuka Y, Yamaguchi T, Kanda Y, Morishima Y, Fukuda T, Miyazaki Y, Nakamae H, Tanaka J, Atsuta Y, Kanamori H. Takami A, et al. Among authors: yamaguchi t. Biol Blood Marrow Transplant. 2014 Nov;20(11):1785-90. doi: 10.1016/j.bbmt.2014.07.010. Epub 2014 Jul 14. Biol Blood Marrow Transplant. 2014. PMID: 25034960 Free article.
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T. Takenaka K, et al. Among authors: yamaguchi t. Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26. Biol Blood Marrow Transplant. 2015. PMID: 26211985 Free article.
Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT.
Ishiyama K, Yamaguchi T, Eto T, Ohashi K, Uchida N, Kanamori H, Fukuda T, Miyamura K, Inoue Y, Taguchi J, Mori T, Iwato K, Morishima Y, Nagamura-Inoue T, Atsuta Y, Sakamaki H, Takami A. Ishiyama K, et al. Among authors: yamaguchi t. Leuk Res. 2016 Aug;47:47-53. doi: 10.1016/j.leukres.2016.04.017. Epub 2016 May 12. Leuk Res. 2016. PMID: 27244257
The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse.
Kurosawa S, Yamaguchi H, Yamaguchi T, Fukunaga K, Yui S, Kanamori H, Usuki K, Uoshima N, Yanada M, Takeuchi J, Mizuno I, Kanda J, Okamura H, Yano S, Tashiro H, Shindo T, Chiba S, Tomiyama J, Inokuchi K, Fukuda T. Kurosawa S, et al. Among authors: yamaguchi t, yamaguchi h. Int J Hematol. 2020 Aug;112(2):200-209. doi: 10.1007/s12185-020-02894-x. Epub 2020 Jun 3. Int J Hematol. 2020. PMID: 32495317
9,375 results